ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer – Yahoo Finance

by

  1. ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer Yahoo Finance
  2. Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma Medical Xpress
  3. Mirvetuximab Soravtansine Improves Survival in Patients With Recurrent Ovarian Cancer The ASCO Post
  4. ImmunoGen Shares Rally Premarket on Elahere Study Data >IMGN MarketWatch
  5. New Ovarian Cancer Drug Extends Survival in Resistant Disease Medpage Today
  6. View Full Coverage on Google News

Read original article here

Leave a Comment